explore -WSS

explore

author：hotspot 2025-09-02 08:21:47 - browse：9848

insulin biosimilar — The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. Jacquelyn Martin/AP

A group representing clinical labs across the country sued the Food and Drug Administration on Wednesday over the agency’s plan to actively regulate lab-developed tests.

The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. When the FDA finalized its test regulation plan last month, several experts said it was only a matter of time until someone in the lab industry sued.

Tests made in labs have historically gone unregulated by the FDA, as the agency considered them low-risk when it started regulating medical devices in 1976. But the tests have since become more numerous and complex, and the regulatory gray area enabled unreliable tests to thrive and harm patients. Infamous examples include Theranos’ blood tests, as well as misleading prenatal genetic tests from a range of companies.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Death of patient in Alzheimer’s trial raises question of possible risks

Wikipedia

focus

hotspot

WSS

Death of patient in Alzheimer’s trial raises question of possible risks

Death of patient in Alzheimer’s trial raises question of possible risks

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Colonoscopy at 40? Study finds a possible benefit

Why drug prescriptions should include diagnoses

Disclosing genetic information: not as worrisome as once feared

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

In age of alternative facts, a scholarly course on calling out crap

Do masks work? RCTs can't tell us

Malaria cases in Florida and Texas: Here’s what you need to know

In areas with more Black doctors, Black people live longer

Heart attack and stroke risk calculators need revising

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

State Dept. review finds Biden bears some blame for Afghanistan failures

Cloning humans is technically possible. It's curious no one has tried

As demand for Covid shots wanes, Moderna seeks its next success

‘Oppenheimer’ and the risks of AI in health care

entertainment

NIH launches clinical trials and new research office for long Covid

Ask STAT: What do you want to know about ChatGPT in medicine?

Ask STAT: What do you want to know about ChatGPT in medicine?

Disclosing genetic information: not as worrisome as once feared

Adults seen as increasingly susceptible to measles

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Wikipedia

focus

hotspot

knowledge